Terasawa M, Tomomatsu N, Maruyama Y
Research Laboratories, Yoshitomi Pharmaceutical Industries Ltd., Fukuoka, Japan.
Nihon Yakurigaku Zasshi. 1988 Jul;92(1):11-6. doi: 10.1254/fpj.92.11.
The anti-allergic actions of traxanox sodium pentahydrate (traxanox) were examined using experimental allergic rhinitis models. Traxanox (10 and 30 mg/kg, p.o.), tranilast (30 and 100 mg/kg, p.o.) and disodium cromoglycate (DSCG, 3 and 10 mg/kg, i.v.) dose-dependently inhibited the increase of dye leakage in rats actively sensitized with dinitrophenol-coupled ascaris extract. Traxanox was about 4 times more potent than tranilast. In this test, the inhibitory activity of traxanox (30 mg/kg, p.o.) was not affected by predosing with the same dose for 7 days. In addition, traxanox (1-10 mg/kg, i.v.) inhibited the allergically induced increase in nasal resistance of guinea pigs actively sensitized with egg albumin, while tranilast (10 mg/kg, i.v.), DSCG (100 mg/kg, i.v.) and mepyramine (1 mg/kg, i.v.) had little effect. These results suggest that traxanox may be clinically effective in treating patients with nasal allergies.
使用实验性变应性鼻炎模型研究了五水曲尼司特钠(曲尼司特)的抗过敏作用。曲尼司特(10和30毫克/千克,口服)、曲尼司特(30和100毫克/千克,口服)和色甘酸二钠(DSCG,3和10毫克/千克,静脉注射)剂量依赖性地抑制了用二硝基苯酚偶联蛔虫提取物主动致敏的大鼠染料渗漏的增加。曲尼司特的效力约为曲尼司特的4倍。在该试验中,曲尼司特(30毫克/千克,口服)的抑制活性不受相同剂量预给药7天的影响。此外,曲尼司特(1-10毫克/千克,静脉注射)抑制了用卵清蛋白主动致敏的豚鼠变应性诱导的鼻阻力增加,而曲尼司特(10毫克/千克,静脉注射)、DSCG(100毫克/千克,静脉注射)和甲氧苄氨嘧啶(1毫克/千克,静脉注射)几乎没有作用。这些结果表明,曲尼司特可能在临床上对治疗鼻过敏患者有效。